Kornimate/medical-research-clean huggingface dataset:
superficial, cervical block in thyroid surgery, a randomized controlled trial

Conditions: Thyroidectomy

Summary: the study investigates the impact on post-operative pain of the superficial cervical block with bupivacaine combined with subcutaneous infiltration of the incisional area in thyroid surgery under general anesthesia. in addition, cost savings using the cervical block are evaluated (due to reduced length of hospital stay). the study is prospective, randomized, double blind, and placebo-controlled. the study is performed at the department of surgery, cantonal hospital of st. gallen.


Eligibility criteria:
inclusion criteria: * elective thyroid or combined thyroid/parathyroid surgery, restricted to the central cervical compartment * informed consent exclusion criteria: * intolerance to used medication * recurrent disease * neck dissection, sternotomy * emergency surgery

Keywords: surgery thyroid gland cervical block pain, postoperative
the effect of yoga and laughter yoga on increasing the psychological resilience of mothers

Conditions: Depression; Stress; Anxiety; Psychological Resilience

Summary: objective: the study will carried out in a randomized controlled trial to determine the effect of yoga and laughter yoga on increasing the psychological resilience of mothers with their babies in the neonatal intensive care unit method: the research will be carried out with mothers whose babies are treated in the neonatal intensive care unit. mothers will be divided into three groups as yoga (n=20), laughter yoga (n=20) and control (n=20) by block randomization method. research findings; data form will obtained by using "introductory characteristics form", "depression, anxiety, stress scale (dass-21)" and "psychological resilience scale".

starting from the 1st week (5-7 days) after the birth, mothers will be given 10 sessions of laughter yoga (laughter group) and yoga (yoga group) twice a week for 45 minutes.dass-21 and resilience scale will be administered to mothers in all groups at 1st, 3rd and 5th weeks.

Eligibility criteria:
inclusion criteria: * mothers who are older than 18 years of age, * whose gestational week is less than 32 weeks, * whose baby has been treated in the neonatal intensive care unit for at least one week, * who have internet access exclusion criteria: * mothers with a genetic disease or congenital anomaly in their baby

Keywords: psychological resilience depression stress anxiety nursing
neuroprotection by cannabinoids in huntington's disease

Conditions: Huntington's Disease

Summary: huntington's disease (hd) is a progressive neurodegenerative disorder, related to an abnormal expansion of cag triplets in the huntingtin gene, characterized by motor, cognitive and behavioral abnormalities, without known effective symptomatic treatment and without known disease slowing strategy. the most severe neuropathological lesions observed in hd take place in the striatum, one brain area important in motor control and rich in cannabinoid receptors (cbr). cbr are subdivided in two classes: cb1r are located in neurons and play a role in neuronal function; cb2r in brain are located mostly in microglia and modulate neuroinflammation. cbr disappear early in the course of hd, before there is a massive drop out of cells in the striatum. cannabinoid transmission is also an early event in brains of animal models of hd. in r6/2 mice, which carry large cag expansions and develop an early and severe hd phenotype the suppression of the cb1r gene further accelerate the development of a severe clinical syndrome and the characteristic brain inclusions and abnormalities of synaptic density. r6/2 treated mice treated with cannabinoids improve their clinical phenotype, their brain lesions, the synaptic density and the levels of bndf, a neurotrophic factor which enhances survival and resistance of striatal neurons. preliminary studies of cannabinoids in patients with hd have shown that these compounds are safe in these patients. those studies, however, did not show efficacy because 1) they were underpowered from the statistical point of view, 2) were performed with isolated pure cannabinoids, instead of the more physiological stimulation with a mixture of compounds, and 3) they did use insensitive clinical parameters instead of sensitive end points, such as pathogenically important biomarkers. the investigators propose a phase ii trial with combination of cannabinoids with evaluation of safety, by the profile of adverse events, and efficacy, according to changes of important biomarkers


Eligibility criteria:
inclusion criteria: 1. patients with hd 2. older than 18 years. 3. able to understand the study, to attend the study visits and to provide informed consent. 4. stable baseline medication for at least 6 weeks prior to randomization. 5. score in the uhdrs-motor from 5 to 50. 6. good cognitive status (mmse\> 25) at the screening visit, with no evidence of major depression, at the discretion of the attending physician, and no evidence of psychosis. 7. not consumers of products derived from marijuana. exclusion criteria: 1. pregnant or lactating women. 2. history of drug addition. 3. history of psychosis or with history of suicidal attempt. 4. patients with diseases of the oral cavity that prevents the safe administration of the drug. 5. patients in which drug administration is contraindicated according to the smpc

Keywords: huntington's disease, cannabinoids
comparison of absorption of vitamin d in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the investigators predict that a powder pill form of vitamin d will be more effectively absorbed than an oil form of vitamin d in people diagnosed with cystic fibrosis.

the purpose of this study is to see how well two different forms of vitamin d work in cystic fibrosis (cf). patients with cystic fibrosis have a hard time absorbing certain foods and often have low vitamin d levels. studies show that vitamin d may help fight infections common in cystic fibrosis. the investigators would like to see if a powder pill form of vitamin d will work better than a pill mixed with oil. each person will randomly receive either a powder pill or an oil based pill. blood will be tested while during a 3-4 day hospital stay. the investigators plan to enroll no more than 24 patients with cf from emory university hospital for this study.

Eligibility criteria:
inclusion criteria: * adult cf patients (age \>18 years * able to tolerate oral medication * expected to survive the duration of the study exclusion criteria: * inability to obtain or declined informed consent from the subject and/or legally authorized representative * history of disorders associated with hypercalcemia * current hypercalcemia (albumin-corrected serum calcium \>10.8 mg/dl or ionized calcium \>5.2 mg/dl) * chronic kidney disease worse than stage iii (\<60 ml/min), 7) forced expiratory volume (fev1)% predicted \<20% * current significant hepatic dysfunction total bilirubin \> 2.5 mg/dl with direct bilirubin \> 1.0 mg/dl * current use of cytotoxic or immunosuppressive drugs * history of aids or illicit drug abuse * too ill to participate in study based on investigator's or study team's opinion * current enrollment in another intervention trial

Keywords: cystic fibrosis vitamin d absorption vitamin deficiency fat soluble
neurocognitive assessment in tavi

Conditions: Aortic Valve Disease

Summary: severe aortic stenosis is a common heart condition affecting elderly patients. degeneration of the aortic valve (oneway valve between the heart and the aorta) causes high resistence to blood flow, resulting in strain on the heart and the potential for heart failure and death. treatment of aortic stenosis has traditionally been with open heart surgery. a new procedure called transcatheter aortic valve implantation (tavi) allows new aortic valves to be implanted through the femoral arteries, resulting in equivalent outcomes to open surgery with a more rapid recovery. some complications remain present however, including the risk of debris released during the valve implantation being carried by the blood stream into the brain. this may lead to strokes and a loss of mental capacity. devices that filter the blood stream and capture this debris have now been developed but are of uncertain benefit. we plan to investigate the brain function of patients who have been randomly assigned to the tavi procedure with and without the use of filters to see if there are any cognitive benefits to the use of this technology. patients who are enrolled in the bhf protect-tavi trial will be invited to partcipate in this trial. they will have already been randomly assigned to tavi with or without cerebral filter use. we will perform a series of bedside clinical tests (lasting \~40 minutes) involving questionnaires, pen \& paper and computer-based tasks. these will be performed both pre- and post-tavi. there is no change to routine patient care. data will be analysed with the assistance of trained neuropsychologists and will provide a valuable insight into the performance and role of the cerebral filter for tavi patients in the future.


Eligibility criteria:
inclusion criteria: * randomised in the bhf protect-tavi trial (assessing stroke outcomes in tavi with and without filter use). * willing to provide informed consent for participation in this trial. exclusion criteria: * participant has been excluded from use of the filter device due to anatomical or clinical contra-indications. * inadequate english skills. * inability to complete assessment tasks due to visual or auditory impairment.
a randomized, double-blind, multicenter study to evaluate the acid-inhibitory and dose-response efficacy of tak-438 (20 mg, 40 mg) in patients with proton pump inhibitor (ppi) - resistant erosive esophagitis

Conditions: Erosive Esophagitis

Summary: the purpose of this study is to evaluate the acid-inhibitory and dose-response efficacy of tak-438 (20 mg, 40 mg) in patients with ppi-resistant erosive esophagitis.


Eligibility criteria:
inclusion criteria: 1. the participant has been treated with standard-dose or higher-than-standard-dose ppi until immediately before the start of the observation phase. 2. outpatient (in principle) 3. at the endoscopy scheduled for the observation phase (visit 2), the participant must have endoscopically confirmed reflux esophagitis of grade a to d, as defined by the la classification grading system, which remains insufficiently controlled with standard-dose or higher-than-standard-dose ppi therapy. 4. the participant showed good compliance to the study medication in the observation phase (compliance rate 80% or more). exclusion criteria: 1. participants with an esophagus-related complication (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis, etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or physiochemical trauma (esophageal sclerotherapy, etc.). however, participants with schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or barrett's esophagus are allowed to be included. 2. participants who have received surgery or treatment affecting gastroesophageal reflux (cardioplasty, dilation of esophageal stenosis \[excluding schatzki's ring\], etc.), or who have a history of surgery of stomach or duodenum (excluding removal of benign polyp under endoscopy) 3. participants who have acute upper gastrointestinal bleeding, gastric or duodenal ulcer (mucosal defect with white coating) at the start of the observation phase (visit 1) or at endoscopy during the observation phase (visit 2) . however, participants with gastric or duodenal erosions are allowed to be included. 4. participants with a previous or current history of zollinger-ellison syndrome, or other gastric acid hypersecretion disorders.
to investigate the safety and efficacy of ub-421 monotherapy in hiv infected adults

Conditions: HIV-1 Infection

Summary: the purpose of this phase ii study is to evaluate the safety, tolerability and efficacy of two multi-dose regimens of ub-421 monotherapy in replacement of haart in hiv-1 infected adults with virological suppression.

this is an open-label, phase ii study to evaluate the safety, tolerability and efficacy of two multi-dose regimens of ub-421 monotherapy in replacement of haart in hiv-1 infected adults with virological suppression. in this study, approximately 29 subjects will be enrolled to receive one of the two ub-421 regimens as the monotherapy in replacement of harrt treatment. subjects assigned to cohort 1 will receive ub-421 infusion at 10 mg/kg weekly for 8 weeks; subjects assigned to cohort 2 will receive ub-421 infusion at 25 mg/kg bi-weekly for 16 weeks.

Eligibility criteria:
inclusion criteria: * hiv-1 sero-positive * aged 20 years or older * have received haart treatment * cd4+ t cell count ≧ 350 cells/mm3 * hiv-1 plasma rna level remains below the limit of * were not breastfeeding for women * subjects with a negative serum pregnancy test result at screening visit for women of childbearing potential * subjects agree on using birth control barrier (female or male condom) during the entire study period * subjects sign the informed consent before undergoing any study procedures exclusion criteria: * any active infection except for hiv, and required immediate therapy * any active aids-defining illness per category b and category c conditions according to the u.s. centers for disease control and prevention (cdc) classification system for hiv infection * any documented cd4+ t cell count \< 200 cells/mm3 within the past 12 weeks before screening visit * any significant diseases (other than hiv-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from screening, medical history, and/or physical examination that, in the investigator's opinion, would preclude the subject from participating in this study * any vaccination within 8 weeks prior to the first dose of study drug * any immunomodulating therapy (including interferon and steroid) or systemic chemotherapy within 12 weeks prior to the first dose of study drug * any illicit intravenous drugs within 12 weeks prior to the first dose of study drug * any current alcohol or illicit drug use that, in the investigator's opinion, will interfere with the subject's ability to comply with the dosing, visit schedules and protocol evaluations * more than one change of haart regimen because of virologic failure
neuroimaging studies of chronic primary headaches using positron emission tomography and magnetic resonance imaging

Conditions: Migraine; Chronic Migraine

Summary: investigators hypothesize that chronic primary headaches are accompanied by a discrete pattern of brain metabolism and activity involving brain structures related to the development of acute exacerbations as well as pain modulation. such structures include the brainstem, hypothalamus, and orbitofrontal cortex and can be defined using functional brain imaging.

specific aims of the study include: 1. to determine the pattern of brain metabolism using positron emission tomography (pet) found in chronic migraine, episodic migraine and control patients. 2. to determine changes of resting state brain networks using magnetic resonance imaging (mri) between patients with chronic or episodic headache and healthy volunteers.

Eligibility criteria:
inclusion criteria: * patients aged 18-65 * no medical contraindication. chronic headache group: * patients with chronic primary headaches who are experiencing phases with background pain as well as habitual pain exacerbations. * able to provide informed consent. * not pregnant or planning to become so, with a pregnancy test prior to scanning. control group and episodic migraine group: * patients with episodic migraine * able to provide informed consent. * not pregnant or planning to become so, with a pregnancy test prior to scanning. exclusion criteria: * taking a migraine preventive currently or in the last fifteen days. * known claustrophobia * patient is pregnant, planning to be pregnant, or becomes pregnant. * patients with metal implants. * patients who have had a study involving radiation within the one year prior to enrolling in this study

Keywords: episodic migraine chronic migraine magnetic resonance imaging positron emission tomography
an evaluation of home-based telemedicine services

Conditions: Congestive Heart Failure; Chronic Obstructive Pulmonary Disease; Diabetes

Summary: tele-home health care, which providers for video interactions between home-based veterans and home care nurses, is a potentially useful adjunct to home care services. however, few randomized trials have been conducted of this technology.

background: tele-home health care, which providers for video interactions between home-based veterans and home care nurses, is a potentially useful adjunct to home care services. however, few randomized trials have been conducted of this technology. objectives: the primary objectives were to determine if tele-home health care patients, compared with patients receiving usual home care, have:1) higher levels of health related quality of life and home care satisfaction; 2) fewer inpatient admissions, hospital stays, and outpatient and emergency room visits; and 3) higher levels of home care access, in terms of the total number of contacts between hbpc nurses and patients. methods: patients were randomly assigned to the intervention or to the control group. video tele-health units were installed in patient homes for the intervention group, and control group patients received usual home care services. baseline and six month follow up surveys included questions on perceived health related quality of life and home care satisfaction. t-tests were used to compare intervention and control group members in terms of six month changes in health related quality of life and satisfaction with home care. multivariate analyses were used to assess group differences in six month health care service use, with prior service use and survival included as covariates. status: the study is completed, with a final enrollment of 37 patients. three study manuscrip\[ts have been completed (two published and one under review).

Eligibility criteria:
inclusion criteria: patients must be enrolled in the home care program at the indianapolis vamc and have at least: (a) 6 outpatient visits, one hospitalization, or 2 or more emergency room visits in the last twelve months, (b) a care plan specifying two or more skilled nursing visits per month, (c) an expected need for future home care visits for at least one month. exclusion criteria:
methylphenidate on intracortical inhibition in methamphetamine abusers attention deficit hyperactivity disorder (adhd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: previous studies using transcranial magnetic stimulation (tms) with paired pulse protocols have shown that a conditioning tms pulse applied to the human motor cortex changes the excitability of motor pathways from the motor cortex to spinal motorneurons. these effects depended on the stimulus intensity of both conditioning and test pulse and also the isi). a characteristical sequence of inhibition (short interval cortical inhibition \[sici\], gaba-aerg), facilitation (intracortical facilitation \[icf\]), and inhibition again (long interval cortical inhibition \[lici\], gaba-berg) is thought to be physiologically involved in motor control. previous studies have also shown that neuronal inhibitory motor circuits are also disturbed in adhd which will be restored by using methylphenidate. in this study the investigators sought to investigate if methamphetamine abuse (from the same chemical class of medications) will alter such effects of methylphenidate.

design: prospective, randomized, -controlled (1:1 randomization), duration-2 single sessions one week apart setting: university psychiatric hospitals in tehran including roozbeh hospital, rasool hospital and imam hossein general hospital will refer clients to iranian national center for addiction studies, tehran university of medical sciences. patients: fifteen patients with methamphetamine abuse for at least 2 years plus adhd are compared with a control group of 15 adhd patients matched for age and gender intervention: we administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. a paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired tms pulses (conditioning and test pulse) in an intermixed randomized order. short interval cortical inhibition is measured with an inter-stimulus intervals (isi) of 3 msec and a stimulator output of 80% rmt for the conditioning stimulus and 1mvt stimulation intensity for the test stimulus. icf investigation is measured with an isi of 13 msec), with the condition of an isi of 50 msec (isi 50) and both stimuli applied with 1mvt intensity). long interval cortical inhibition (lici) is measured with isis of 100 msec (isi 100), 200 msec (isi 200), and 300 msec (isi 300); both stimuli with 1mvt intensity.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of methamphetamine abuse co morbid with adhd * right handedness exclusion criteria: * other current axis i disorders (except simple phobia and nicotine addiction) * personal or close family history of seizure disorder * ferromagnetic material in body or close to head * neurologic disorder * pregnancy * taking medications known to lower seizure threshold (eg, theophylline)

Keywords: paired transcranial magnetic stimulation methamphetamine abuse, adhd, methylphenidate we study the effect of methamphetamine abuse on intracortical inhibition, in adhd patients, treated with methylphenidate.
prospective observational study of peri-implantation serum hcg levels

Conditions: Infertility

Summary: the purpose of this study is to prospectively define a set of data suitable for developing models of pregnancy viability. those models will be based on serum hcg concentration measured during the peri-implantation period in patients that received fresh embryo transfer and those that received transfer of frozen-thawed embryos, and to compare and contrast these models. this may reveal insights into differences between these types of ivf cycles.

the current study seeks to examine the effect of the timing of implantation (as indicated by the first increase in serum hcg level) on the viability of pregnancies and to determine if such effect of timing differs between fresh embryo transfers and frozen-thawed embryos transfers. in this case, the timing of implantation will be measured through serum hcg analysis on days 3, 4, 5, and 7 after blastocyst transfer.

Eligibility criteria:
inclusion criteria: * ivf patients (adults) who received blastocyst transfer exclusion criteria: * those patients using different laboratories